Skip to main content

Advertisement

Table 1 Patient characteristics and treatment

From: Radiotherapy with or without androgen deprivation therapy in intermediate risk prostate cancer?

Characteristic IR RT alone (n = 177) IR RT+ ADT (n = 196) P
Age (mean ± SD, years) 72 ± 5.34 72 ± 5.85 0.934
Pretreatment PSA (ng/mL) 7.88 ± 3.55 9.34 ± 3.97 0.001>
Fiducials implant % (n) 71.8 (127) 65.3 (128) 0.181
Gleason score % (n) 0.257
 5 or 6 19.8 (35) 15.8 (31)  
 7 (3 + 4) 52.5 (93) 49.0 (96)  
 7 (4 + 3) 27.7 (49) 35.2 (69)  
T- stage % (n) 0.074
 T1 31.4 (50) 23.4 (37)  
 T2a-b 64.8 (103) 67.7 (107)  
 T2c 3.8 (6) 8.9 (14)  
No. IR risk factors % (n) 0.001>
 1 65.0 (115) 42.6 (83)  
 2 31.1 (55) 48.7 (95)  
 3 4.0 (7) 8.7 (17)  
RT treatment modality % (n) 0.929
 3D 17.2 (29) 15.7 (29)  
 IMRT 23.1 (39) 23.8 (44)  
 VMAT 59.8 (101) 60.5 (112)  
RT lymph-nodes % (n) 2.8 (5) 10.7 (21) 0.003
Positive biopsy cores % (mean ± SD) 45.33 ± 25.56 52.56 ± 27.61 0.017
Charlson comorbidity index 0.774
 2 49.4 (80) 52.0 (93)  
 3 16.7 (27) 14.0 (25)  
 4≤ 34.0 (55) 34.1 (61)  
Months follow-up 57.6 ± 36.9 54.3 ± 37.4 0.383